2. Academic Validation
  3. RET, ROS1 and ALK fusions in lung cancer

RET, ROS1 and ALK fusions in lung cancer

  • Nat Med. 2012 Feb 12;18(3):378-81. doi: 10.1038/nm.2658.
Kengo Takeuchi 1,  Manabu Soda,  Yuki Togashi,  Ritsuro Suzuki,  Seiji Sakata,  Satoko Hatano,  Reimi Asaka,  Wakako Hamanaka,  Hironori Ninomiya,  Hirofumi Uehara,  Young Lim Choi,  Yukitoshi Satoh,  Sakae Okumura,  Ken Nakagawa,  Hiroyuki Mano,  Yuichi Ishikawa
Affiliations

Affiliation

  • 1 Pathology Project for Molecular Targets, the Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. [email protected]
PMID: 22327623 DOI: 10.1038/nm.2658
Abstract

Through an integrated molecular- and histopathology-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-positive and 13 ROS1-fusion-positive adenocarcinomas, including for unidentified fusion partners for ROS1. In addition, we discovered previously unidentified kinase fusions that may be promising for molecular-targeted therapy, Kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain containing 6 (CCDC6)-RET, in 14 adenocarcinomas. A multivariate analysis of 1,116 adenocarcinomas containing these 71 kinase-fusion-positive adenocarcinomas identified four independent factors that are indicators of poor prognosis: age ≥ 50 years, male sex, high pathological stage and negative kinase-fusion status.

Figures